^
No biomarker
Burkitt Lymphoma
cyclophosphamide oral
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
rituximab
Sensitive: A1 - Approval
No biomarker
Burkitt Lymphoma
CODOX-M + rituximab
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
R-CVAD
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
R-CVAD + cytarabine + methotrexate
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
EPOCH-R
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RGDP
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RICE
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RIVAC + methotrexate
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RIVAC
Sensitive: A2 - Guideline
No biomarker
Burkitt Lymphoma
RICE + methotrexate
Sensitive: A2 - Guideline
LDH elevation
Burkitt Lymphoma
ViPOR
Sensitive: C3 – Early Trials
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
cytarabine + ifosfamide + etoposide IV + methotrexate + dexamethasone
Sensitive: C4 – Case Studies
TP53 T175H + PIK3CA H1047R
Burkitt Lymphoma
idelalisib
Sensitive: C4 – Case Studies
TP53 A159V
Burkitt Lymphoma
PZ01
Sensitive: C4 – Case Studies
CD19 positive + CD20 positive
Burkitt Lymphoma
rituximab + FT596
Sensitive: D – Preclinical
LY9 expression
Burkitt Lymphoma
T-lymphocyte cell therapy
Sensitive: D – Preclinical